<\/span><\/h3>\nThe 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Caplin Point Laboratories. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% \u2014 the key downside risk to the Caplin Point share price target 2026<\/strong> consensus of Rs 2,212-2,557.<\/p>\n<\/span>2. Valuation at 22x Requires Consistent Execution<\/strong><\/span><\/h3>\nAt 22x trailing P\/E, Caplin Point Laboratories is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression \u2014 the most immediate risk to the Caplin Point share price target 2026<\/strong>. The Rs 1,507 52-week low zone is the key support and stop-loss reference.<\/p>\n<\/span>3. Competition Intensifying in Pharma<\/strong><\/span><\/h3>\nDomestic and global competitors are investing aggressively in Caplin Point Laboratories’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Caplin Point share price target 2026<\/strong>.<\/p>\n<\/span>4. Input Cost and Supply Chain Volatility<\/strong><\/span><\/h3>\nCommodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates \u2014 creating downside risk to the Caplin Point share price target 2026<\/strong> of Rs 2,212-2,557.<\/p>\n<\/span>5. FII Selling Risk \u2014 8.4% Institutional Holding<\/strong><\/span><\/h3>\nWith 8.4% FII ownership, Caplin Point Laboratories is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Caplin Point share price target 2026<\/strong> analyst consensus of Rs 2,212-2,557.<\/p>\n<\/span>Caplin Point Laboratories Bull Case vs Bear Case \u2014 Caplin Point share price target 2026<\/strong><\/span><\/h2>\n\n\n\n| Scenario<\/th>\n | Price Target<\/th>\n | Probability<\/th>\n | Trigger<\/th>\n<\/tr>\n |
\n| Bull Case<\/td>\n | 2,557<\/td>\n | Medium<\/td>\n | FY27 earnings beat, FII re-entry, sector re-rating<\/td>\n<\/tr>\n |
\n| Base Case<\/td>\n | Rs 2,212-2,557<\/td>\n | High<\/td>\n | FY27 in-line earnings, stable macro<\/td>\n<\/tr>\n |
\n| Bear Case<\/td>\n | Rs 1,507 zone<\/td>\n | Low<\/td>\n | FY27 guidance cut, prolonged FII selling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/span>Caplin Point Laboratories Share Price Reference Table<\/strong><\/span><\/h2>\n\n\n\n| NSE Symbol<\/td>\n | CAPLIPOINT<\/td>\n<\/tr>\n | \n| CMP<\/td>\n | Rs 1,857<\/td>\n<\/tr>\n | \n| 52-Week High<\/td>\n | Rs 2,512<\/td>\n<\/tr>\n | \n| 52-Week Low<\/td>\n | Rs 1,507<\/td>\n<\/tr>\n | \n| Market Cap<\/td>\n | Rs 13,800 Cr<\/td>\n<\/tr>\n | \n| P\/E<\/td>\n | 22x<\/td>\n<\/tr>\n | \n| Promoter<\/td>\n | 66.9%<\/td>\n<\/tr>\n | \n| FII<\/td>\n | 8.4%<\/td>\n<\/tr>\n | \n| Dividend FY26<\/td>\n | Rs 20<\/td>\n<\/tr>\n | \n| Short-Term Target<\/td>\n | Rs 2,212<\/td>\n<\/tr>\n | \n| 12M Target<\/td>\n | Rs 2,212-2,557<\/td>\n<\/tr>\n | \n| Upside<\/td>\n | 19-38%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Sources: NSE\/BSE, Screener.in, publicly available analyst research. April 2026.<\/em><\/p>\n<\/span>Analyst Ratings and Caplin Point share price target 2026<\/strong><\/span><\/h2>\n | |